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NADH:quinone oxidoreductase (PfNDH2) represents a
metabolic choke point in the respiratory chain of Plasmo-
dium falciparum mitochondria and is the focus of a drug
discovery programme. A miniaturised assay for recombi-
nant PfNDH2 with robust assay performance measures
was generated for the high throughput screening (HTS) of
a focused library of 17,000 drug-like compounds. A quan-
titative structure-activity relationship has been developed
around one of the chemical templates derived from the
HTS hits. Lead molecules developed to date show selective
inhibitory activity against PfNDH2 versus P. falciparum
bc1 or dihydroorotate dehydrogenase (DHODH). Potent
enzyme inhibition is accompanied by in vitro parasite kill
of multidrug-resistant strains in the low nM range and
clearance of parasites from in vivo P. berghei models. Lead
molecules also display excellent in vitro therapeutic indices
against human cell lines and bovine bc1. Initial metabolic
studies in human liver microsomes and hepatocytes indi-
c a t ef a v o u r a b l ep h a r m a c o l o g y .T h e s ed a t as u p p o r tt h e
further development of this new candidate drug targeting
a novel parasite component.
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